Ceftibuten: Difference between revisions

(Created page with "==General== *Type: *Dosage Forms: *Common Trade Names: ==Adult Dosing== ==Pediatric Dosing== ==Special Populations== *Pregnancy Rating: *Lac...")
 
No edit summary
(8 intermediate revisions by 6 users not shown)
Line 1: Line 1:
==General==
==General==
*Type:  
*Type: Third generation [[cephalosporin]]
*Dosage Forms:
*Dosage Forms: capsule, oral suspension
*Common Trade Names:  
*Dosage Strengths: capsule: 400mg; oral suspension: 90mg/5mL, 180mg/5mL
*Routes of Administration: PO
*Common Trade Names: Cedax


==Adult Dosing==
==Adult Dosing==
===Chronic [[bronchitis]], acute exacerbation===
*400mg PO qd x10 days
===[[Otitis media]], acute===
*400mg PO qd x10 days
===[[Pharyngitis]]/Tonsillitis, streptococcal===
*400mg PO qd x10 days


==Pediatric Dosing==
==Pediatric Dosing==
===[[Otitis media]], acute===
*6 mo - 11 yo, <45kg
**9 mg/kg PO qd x10 days
**Max: 400 mg/day
*12+ yo, >45kg
**400mg PO qd x10 days
===[[Pharyngitis]]/Tonsillitis, streptococcal===
*6 mo - 11 yo, <45kg
**9 mg/kg PO qd x10 days
**Max: 400 mg/day
*12+ yo, >45kg
**400mg PO qd x10 days
===[[Pneumonia]], Community-acquired===
*6 mo - 11 yo, <45kg
**9 mg/kg PO qd x10 days
**Max: 400 mg/day
*12+ yo, >45kg
**400mg PO qd x10 days


==Special Populations==
==Special Populations==
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]:
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: B
*Lactation:
*Lactation: Probably safe
 
*Renal Dosing
*Renal Dosing
**Adult
**Adult
***CrCl 30-49: 200mg qd
***CrCl  5-29: 100mg qd
***CrCl    <5: Not defined
***HD: 400mg after each dialysis
***PD: No supplement
**Pediatric
**Pediatric
***CrCl 30-49: 4.5 mg/kg qd, max 200mg/day
***CrCl  5-29: 2.25 mg/kg qd, max 100mg/day
***CrCl    <5: Not defined
***HD: 9mg/kg after each dialysis, max 400mg;day
***PD: No supplement
*Hepatic Dosing
*Hepatic Dosing
**Adult
**Adult
***Not defined
**Pediatric
**Pediatric
***Not defined


==Contraindications==
==Contraindications==
*Allergy to class/drug
*Hypersensitivity to class/drug
*Caution:
**Hypersensitivity to PCN
**Renal impairment
**Concurrent nephrotoxic agent
**Seizure disorder
**Recent antibiotic-associated colitis


==Adverse Reactions==
==Adverse Reactions==
===Serious===
===Serious===
 
*Allergy to class/drug
*Serum sickness-like reaction
*[[Stevens-Johnson syndrome]]
*Exfoliative dermatitis
*[[Erythema multiforme]]
*Toxic epidermal necrolysis
*Interstitial nephritis
*Superinfection
*C. difficile associated [[diarrhea]]
*[[Seizure]]
*[[Pancytopenia]]
===Common===
===Common===
*[[Nausea]]
*[[Diarrhea]]
*Elevated BUN
*[[Headache]]
*[[Eosinophilia]]
*Dyspepsia
*[[Vomiting]]
*[[Abdominal pain]]
*[[Anemia]]


==Pharmacology==
==Pharmacology==
*Half-life:  
*Half-life: 2-2.5 hr; 13.4 hr if CrCl 5-29
*Metabolism:  
*Metabolism: Other
*Excretion:  
*Excretion: Urine 56%, Feces 39%
*Mechanism of Action:
*Mechanism of Action: Bactericidal; inhibits cell wall mucopeptide synthesis


==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>==
==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>==
Line 154: Line 218:
{{Template:Antibacterial Spectra Key}}
{{Template:Antibacterial Spectra Key}}
==See Also==
==See Also==
*[[Antibiotics (Main)]]


==Source==
==References==
<references/>


<references/>
[[Category:Pharmacology]] [[Category:ID]]

Revision as of 22:02, 19 September 2019

General

  • Type: Third generation cephalosporin
  • Dosage Forms: capsule, oral suspension
  • Dosage Strengths: capsule: 400mg; oral suspension: 90mg/5mL, 180mg/5mL
  • Routes of Administration: PO
  • Common Trade Names: Cedax

Adult Dosing

Chronic bronchitis, acute exacerbation

  • 400mg PO qd x10 days

Otitis media, acute

  • 400mg PO qd x10 days

Pharyngitis/Tonsillitis, streptococcal

  • 400mg PO qd x10 days

Pediatric Dosing

Otitis media, acute

  • 6 mo - 11 yo, <45kg
    • 9 mg/kg PO qd x10 days
    • Max: 400 mg/day
  • 12+ yo, >45kg
    • 400mg PO qd x10 days

Pharyngitis/Tonsillitis, streptococcal

  • 6 mo - 11 yo, <45kg
    • 9 mg/kg PO qd x10 days
    • Max: 400 mg/day
  • 12+ yo, >45kg
    • 400mg PO qd x10 days

Pneumonia, Community-acquired

  • 6 mo - 11 yo, <45kg
    • 9 mg/kg PO qd x10 days
    • Max: 400 mg/day
  • 12+ yo, >45kg
    • 400mg PO qd x10 days

Special Populations

  • Renal Dosing
    • Adult
      • CrCl 30-49: 200mg qd
      • CrCl 5-29: 100mg qd
      • CrCl <5: Not defined
      • HD: 400mg after each dialysis
      • PD: No supplement
    • Pediatric
      • CrCl 30-49: 4.5 mg/kg qd, max 200mg/day
      • CrCl 5-29: 2.25 mg/kg qd, max 100mg/day
      • CrCl <5: Not defined
      • HD: 9mg/kg after each dialysis, max 400mg;day
      • PD: No supplement
  • Hepatic Dosing
    • Adult
      • Not defined
    • Pediatric
      • Not defined

Contraindications

  • Hypersensitivity to class/drug
  • Caution:
    • Hypersensitivity to PCN
    • Renal impairment
    • Concurrent nephrotoxic agent
    • Seizure disorder
    • Recent antibiotic-associated colitis

Adverse Reactions

Serious

Common

Pharmacology

  • Half-life: 2-2.5 hr; 13.4 hr if CrCl 5-29
  • Metabolism: Other
  • Excretion: Urine 56%, Feces 39%
  • Mechanism of Action: Bactericidal; inhibits cell wall mucopeptide synthesis

Antibiotic Sensitivities[1]

Group Organism Sensitivity
Gram Positive Strep. Group A, B, C, G S
Strep. Pneumoniae I
Viridans strep R
Strep. anginosus gp X1
Enterococcus faecalis R
Enterococcus faecium X1
MSSA R
MRSA R
CA-MRSA R
Staph. Epidermidis R
C. jeikeium R
L. monocytogenes R
Gram Negatives N. gonorrhoeae I
N. meningitidis I
Moraxella catarrhalis S
H. influenzae S
E. coli S
Klebsiella sp S
E. coli/Klebsiella ESBL+ R
E coli/Klebsiella KPC+ R
Enterobacter sp, AmpC neg I
Enterobacter sp, AmpC pos R
Serratia sp I
Serratia marcescens X1
Salmonella sp S
Shigella sp S
Proteus mirabilis S
Proteus vulgaris S
Providencia sp. S
Morganella sp. R
Citrobacter freundii R
Citrobacter diversus S
Citrobacter sp. S
Aeromonas sp S
Acinetobacter sp. R
Pseudomonas aeruginosa R
Burkholderia cepacia S
Stenotrophomonas maltophilia R
Yersinia enterocolitica S
Francisella tularensis X1
Brucella sp. X1
Legionella sp. R
Pasteurella multocida X1
Haemophilus ducreyi X1
Vibrio vulnificus X1
Misc Chlamydophila sp X1
Mycoplasm pneumoniae X1
Rickettsia sp X1
Mycobacterium avium X1
Anaerobes Actinomyces X1
Bacteroides fragilis R
Prevotella melaninogenica X1
Clostridium difficile X1
Clostridium (not difficile) X1
Fusobacterium necrophorum X1
Peptostreptococcus sp. X1

Key

  • S susceptible/sensitive (usually)
  • I intermediate (variably susceptible/resistant)
  • R resistant (or not effective clinically)
  • S+ synergistic with cell wall antibiotics
  • U sensitive for UTI only (non systemic infection)
  • X1 no data
  • X2 active in vitro, but not used clinically
  • X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
  • X4 active in vitro, but not clinically effective for strep pneumonia

See Also

References

  1. ↑ Sanford Guide to Antimicrobial Therapy 2014
Retrieved from "https://www.wikem.org/w/index.php?title=Ceftibuten&oldid=229078"